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ABSTRACT
Background Quality indicators are an important
part of the primary care landscape, but focus
strongly on point-in-time measurements, such as
a patient’s last blood pressure (BP) measurement.
There is a larger space of possible measurements,
including ones that more explicitly consider man-
agement over an interval of time.
Objective To determine the predictive abilities of
ﬁve diﬀerent quality indicators related to poor BP
control.
Methods Data from two New Zealand general
practices was analysed on ﬁve BP control indicators
for patients with diagnosed hypertension: 1) last BP
high (>150/90 mmHg); 2) last BP high or no BP
measurement; 3) two or more consistently high BP
measurements for90 days; 4) a high BP then lapse
of >120 days in BPmeasurement; and 5) antihyper-
tensive medication possession ratio (MPR) of
<80%. Probability that a patient would be ident-
iﬁed by each indicator for the nine-month evalu-
ation period ending 31 March 2009 was computed
for each indicator one quarter, two quarters and
three quarters prior to this date. Associations
among the ﬁve indicators for the evaluation period
were also calculated.
Results Positive predictive value (PPV) of indi-
cators for the same indicator nine months later
ranged from 27% (last BP high) to 64% (MPR).
PPVs among the ﬁve measures with respect to the
same time period ranged from 9% to 77% (median
33%).
Conclusions Modest PPVs between indicators
suggest the importance of considering multiple
indicators to incentivise best management across
diverse aspects of BP control.
Keywords: clinical audit, long-term care, patient
outcome assessment, quality and outcomes frame-
work, quality indicators
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Introduction
Despite various eﬀorts to control blood pressure (BP)
to below recommended limits, only 41.9% of treated
patients with hypertension are reported to have con-
trolled BP.1 High BP has been suggested as the most
important risk factor for cardiovascular disease
(CVD) – a British study reported that controlling all
hypertensive patients to a systolic BP of140 mmHg
would yield a reduction of 28–44% in stroke and 20–
35% in ischaemic heart disease, resulting in a total of
125 600 events a year saved in the UK.2
The medical community in general accepts that
following well developed, evidence-based clinical
practice guidelines improves the quality of care
received by patients along with the many other ben-
eﬁts guidelines provide.3 Together with guidelines,
quality indicators are often used in order to provide
feedback to clinicians and to give an indication of the
quality of patient care delivered. There have been
national level eﬀorts to develop quality indicators
for primary care, notably from Canada,4 New
Zealand,5 Denmark6 and the UK.7 The Quality and
Outcomes Framework (QOF) in the UK7 is perhaps
the world’s single largest attempt to improve the
quality of primary care8 (see Box 1).
The key QOF indicator ‘BP5’ uses the notion of the
‘last BP’ being controlled. Previously,9–11 we developed
several quality indicators with a strong association to
temporal intervals (an evaluation period), rather than
focusing on a singlemeasurement at one point in time.
The QOF’s BP5 suggests that its framers saw relevance
in nine months as an appropriate evaluation period
(and, we acknowledge, in this sense BP5 is at least
partially interval based). In this paper we examine
ﬁve BP quality indicators ranging from a completely
point-in-time ‘last BP high’ measure to a range of
more interval-oriented indicators. We look at their
stability (ability to predict the same indicator) over
time and their association with each other. We use
routinely collected data from two general practices in
New Zealand for illustration.
Methods
Quality indicators
In previous work on indicators based on electronic
medical records (EMRs)we developed audit criteria to
identify hypertensive patients who needed follow-up.
The researchers had iterative discussions with an expert
panel from a general practice, including the practice
manager, two general practitioners (GPs) and practice
nurses. These discussions yielded eight indicators of
quality improvement opportunities, which were subse-
quently validated.9 Two indicators (with modiﬁed
thresholds for comparability) are relevant to BP5:
‘patients classiﬁed with hypertension with two or more
consistently high BP measurements (>150/90 mmHg)
over 90 days or more where either (i) the last of these
high BPs was within the evaluation period or (ii) with no
subsequently ‘controlled’ BP (150/90 mmHg) measure-
ment after the consistently high BPs’
and
‘patients classiﬁed with hypertension with a BP measure-
ment >150/90 mmHg followed by a gap of >120 days in
BP measurements extending into the evaluation period’
The ‘evaluation period’ was nine months in the
present study, in order to be consistent with the BP5
indicator used in QOF. We use the six-month period
prior to the evaluation period as a ‘run-in’ period to
account for intervals of suboptimal management that
begin before the evaluation period but extend into it.10
We also use an indicator of medication adherence,
medication possession ratio (MPR, percentage of days
a patient had medication supply during an evaluation
period) and take MPR<80% as the indicator level.
Details related toMPR and the importance of it for BP
control have been reported previously.10 Similar to
our previous studies,10,12 we use EMRprescribing data
to determine MPR.
Box 1 The Quality and Outcomes
Framework and ‘point-in-time’ indicators
The QOF was ﬁrst introduced in April 2004 as
part of the General Medical Services contract. It
provides a set of clinical indicators across four
domains (clinical, organisational, additional ser-
vices and patient experience)7 designed around
best practice in order to improve the quality of
service provided to patients. Each indicator is
allocated a number of points andGPpractices are
awarded points according to how well they have
performed, with associated monetary compen-
sation. The indicators are updated annually.
Most of the widely used quality indicators use
the presence of a single point-in-time measure-
ment to determine whether a given indicator is
satisﬁed. For example, an important QOF indi-
cator related to the ongoing management of
patients with hypertension, the one with the
highest point allocation (57 QOF points) in the
‘clinical’ domain, is BP5: ‘The percentage of
patients with hypertension in whom the last
blood pressure (measured in the previous nine
months) is 150/90 or less’.7
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Data extraction
We extracted data for the 24-month period from
1 April 2007 to 31 Mar 2009 with the exception of
classiﬁcations (problems coded using Read Clinical
Codes13), which were extracted for the previous ﬁve
years. The details of the two datasets extracted from
the practices’ EMRs are shown inTable 1.Only funded
patients enrolled at the practices were included (all
New Zealand citizens and permanent residents can be
enrolled with one primary healthcare organisation
which is funded for management of that person;
each general practice is associated with a primary
healthcare organisation). Practice 1 serves a largely
Paciﬁc (particularly Samoan) community in metro-
politan suburbs; Practice 2 serves a largely European
community in a regional city.
Analysis protocol
We analyse failure rates as of the end of the ﬁrst
quarter of 2009 using ﬁve diﬀerent quality indicators:
1) last BP high (>150/90 mmHg); 2) failing BP5;
3) consistently high BP; 4) high BP then lapse; and
5) MPR<80%. Failing BP5 in fact consists of two
patient cohorts – patients with BPs where the last BP
was not controlled (i.e. explicitly high, equivalent to
‘last BP high’), and patients who do not have a BP
measurement during the nine-month period. Using
the ﬁve quality indicators, we determine prediction
rates at one quarter, two quarters and three quarters of
the year prior to the evaluation date to determine the
suitability of each indicator to accurately predict
patients whowill continue to fail each aspect of quality
BPmanagement. The dates of interest are illustrated in
Figure 1.
Using the timelines in Figure 1, we ﬁrst compute the
various rates of failure (i.e. the patient having the
speciﬁc deﬁciency inGPmanagement) as predicted by
the same indicator three-months, six-months and
nine-months prior to 31 March 2009. In terms of
conditional probability, the probability that a patient
will fail an indicator given that the patient failed at a
prior date is given by:
where p(t) indicates the probability that a patient will
fail the indicator during the current evaluation period
while p(t – k) indicates the probability that a patient
will fail the indicator during a time period prior to the
evaluation period (with k of three months, six months
and nine months). This conditional probability is
equivalent to the positive predictive value (PPV) of
the indicator at time t – k for the indicator at time t.
Table 1 Summary of the two practice
data sets for funded and enrolled
patients
Practice 1 Practice 2
Funded and enrolled
patients
5454 4260
Patients with
classiﬁcations
4422 3718
Hypertension 602 674
BP measurements 11 977 9986
Prescriptions 61 840 48 564
Antihypertensives 7663 9981
Figure 1 Timelines related to the quality indicator analysis
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To assess the degree to which the indicators agree
with one another (and hence are potentially ‘redun-
dant’) we look at the conditional probability of a
patient failing one indicator given that they have failed
another with respect to the most current evaluation
period. Again, this conditional probability is equiva-
lent to PPV.
Note that for the MPR criterion there is an ad-
ditional inclusion constraint that a patient is required
to have at least one antihypertensive prescription
during the 15-month period (i.e. during the run-in
period or the evaluation period).
Results
From Practice 1 and Practice 2 respectively, 535 and
598 patients were funded and enrolled at 1 July 2008
and had a hypertension diagnosis; of these, 459 (86%)
and 562 (94%) patients, fromPractice 1 and Practice 2
respectively, satisﬁed the additional inclusion cri-
terion for computation of MPR. The predictive abili-
ties of the ﬁve indicators are shown in Table 2.
These results show that ‘last BP high’, a point-in-
time measure, is less stable than the other, interval-
oriented indicators. Failing BP5 ranks reasonably well;
its PPV is generally under that of consistently high BP,
high BP then lapse and MPR<80% for the three-
month and six-month prior intervals, but this is owed
in part to the interval measures being correlated by
deﬁnition when the time periods overlap. MPR<80%
is the most stable criterion among the ﬁve indicators
considered.
Table 3 and Table 4 show the PPVs between quality
indicators for the two practices at time t; for those
PPVs for which 100% is not deﬁnitional the median is
33% (min = 9%, max = 77%).
Table 2 PPVs of quality indicators based on past performance on same indicator
k Practice Last BP high Failed BP5 Consistently
high BP
High BP then
lapse
MPR<80%
3 months Practice 1 65/118 = 55% 133/190 = 70% 29/39 = 74% 94/118 = 80% 143/166 = 86%
Practice 2 34/77 = 44% 60/105 = 57% 27/35 = 77% 22/27 = 82% 80/99 = 81%
6 months Practice 1 56/142 = 39% 116/198 = 59% 27/51 = 53% 63/101 = 62% 133/184 = 72%
Practice 2 31/85 = 37% 53/113 = 47% 18/38 = 47% 13/24 = 54% 71/110 = 65%
9 months Practice 1 49/156 = 31% 108/210 = 51% 22/45 = 49% 38/82 = 46% 121/188 = 64%
Practice 2 26/96 = 27% 46/124 = 37% 16/41 = 40% 10/22 = 46% 59/104 = 57%
Denominator is patients failing in evaluation period ending at time t – k; numerator is patients failing on ‘current’ evaluation period
(ending at time t) and also failing in evaluation period ending at time t – k
Table 3 PPVs between diﬀerent indicators for Practice 1
Given Last BP high Failed BP5 Consistently
high BP
High BP then
lapse
MPR
<80%
n (%) n (%) n (%) n (%) n (%)
Last BP high (n = 99) 99 (100) 99 (100) 21 (21) 47 (47) 50 (51)
Failed BP5 (n = 179) 99 (55) 179 (100) 22 (12) 60 (34) 77 (43)
Consistently high BP (n = 38) 21 (55) 22 (58) 38 (100) 22 (58) 17 (45)
High BP then lapse (n = 109) 47 (43) 60 (55) 22 (20) 109 (100) 64 (59)
MPR<80% (n = 163) 50 (31) 77 (47) 17 (10) 64 (39) 163 (100)
The values indicate the number of patients failing an indicator given another indicator failed by n patients, followed by the
corresponding probability (as a percentage)
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Visualisation
As part of the ChronoMedIt framework,12 we devel-
oped a graphical tool that can be used to visualise a
patient’s prescribing patterns togetherwith laboratory
measurements or physiological outcomes, such as BP.
The use of this visualisation tool on a selected patient
results in the plots shown in Figure 2.
The patient shown in Figure 2 has been classiﬁed
with hypertension and has failed all ﬁve indicators.
The last BP is high and therefore satisﬁes the ‘last BP
high’ and ‘failed BP5’ indicators. There are two or
more consistently high BPs as all three measurements
are high with the diﬀerence between ﬁrst and last high
BPs being 386 days. Two instances of high BP then
lapse can be observed in Figure 2: 1) 218 days between
ﬁrst and second BP measurement; and 2) 168 days
between second and third BP measurement. Also,
there are two lapses in antihypertensive therapy (a
lapse of 42 days from 26 August 2008 to 7 October
2008 and of 78 days from 5 January 2009 to 24 March
2009); thus there is total of 120 days without medi-
cation during a 273-day evaluation period, and MPR
= (273–120)/273 = 56.04%, therefore the patient fails
the MPR<80% indicator.
Table 4 PPVs between diﬀerent indicators for Practice 2
Given Last BP high Failed BP5 Consistently
high BP
High BP then
lapse
MPR<80%
n (%) n (%) n (%) n (%) n (%)
Last BP high (n = 75) 75 (100) 75 (100) 12 (16) 25 (33) 21 (28)
Failed BP5 (n = 106) 75 (71) 106 (100) 12 (11) 27 (25) 32 (30)
Consistently high BP (n = 24) 12 (50) 12 (50) 24 (100) 8 (33) 9 (38)
High BP then lapse (n = 35) 25 (71) 27 (77) 8 (23) 35 (100) 22 (63)
MPR<80% (n = 101) 21 (21) 32 (32) 9 (9) 22 (22) 101 (100)
The values indicate the number of patients failing an indicator given another indicator failed by n patients, followed by the
corresponding probability (as a percentage)
Figure 2 Prescribing patterns and BP measurements for a selected patient. The tooltip shows further
information about the selected prescription. The three BP measurements correspond to 3 March 2008,
7 October 2008 and 24 March 2009
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Discussion
Signiﬁcance
This paper illustrated a range of interval-based quality
indicators around management of BP. Our results
indicate that MPR<80% is the most stable measure,
and that all interval-based measures are more stable
than the point-in-time measure of ‘last BP high’. In
our previous research, we showed that nearly a third of
patients satisfying the QOF BP5 criterion fail at least
one of the related interval-based measures; however,
all the indicators demonstrated herein are important
for actively identifying and managing patients on
suboptimal BP control, and the low PPVs shown in
Table 3 and Table 4 indicate that relying on a single
measure is not suﬃcient as the cohorts identiﬁed by
each indicator are considerably diﬀerent. Therefore,
our proposition is that althoughpoint-in-timemeasures
are important, they are not suﬃcient to represent
successful BP control. Notably, with respect to the
QOF, there is warrant to extend this framework to
include indicators that consider BP measurements
over time, and perhaps to consider introducing other
process measures such as MPR. Providing clinicians
with lists of patients who satisfy such indicators may
assist them to actively manage those patients and
ultimately achieve and maintain satisfactory BP con-
trol.
Table 2 shows that at least 74% of the patients from
both practices who failed consistently onhighBP, high
BP then lapse and MPR at the end of 2008 continued
to fail these criteria at the end of the ﬁrst quarter in
2009, demonstrating detectable opportunities for
improved case management. It is interesting to note
from Table 2 that almost all the probabilities are
higher for the Paciﬁc practice than for the European
practice. This is not a surprising result per se, as
research has shown that Maori/Paciﬁc populations
have a higher CVD risk compared with other ethnic
groups.14
Related work
The speciﬁc criteria we have discussed herein (except
‘last BP high’) focus on evaluating clinical outcomes
with respect to time intervals rather than points in
time. Several other studies have also proposed such
indicators,15,16 for example, a set of systematically
developed primary care quality indicators for hyper-
tension included the ‘Percentage of patients with an
average systolic BP greater than 160 mmHg and/or a
diastolic BP greater than 100 mmHg, as determined
on at least three separate visits, who have a diagnosis
of hypertension recorded’.16 It has been shown that
assessing BP control based on a single measurement
and/or a single visit is unlikely to be reliable, but BP
considerations over time result in signiﬁcantly fewer
patients achieving targets set forth by guidelines.15
The interval-based measures proposed herein also
strongly relate to the guidelines17 by the National
Institute for Health and Clinical Excellence (NICE)
in the UK which suggest (recommendation R71)
monitoring BP of a person who has attained and
consistently remained at his or her BP target every
four to six months, and checking for possible adverse
eﬀects of antihypertensive therapy – including the
risks from unnecessarily low blood pressure.
Limitations and future directions
This study has several limitations. The results are
based on just two general practices, and these particu-
lar practices were selected opportunistically (in part
representing the authors’ links and interest with respect
to Paciﬁc health), therefore our results may not gen-
eralise across a population. Also, we have not examined
diﬀerences in management and outcome with respect
to ethnicity (or any other demographic details) in the
present study – this is a worthy direction to take, but
would require a larger, randomised sample. It is worth
noting that the QOF has provision for exception
reporting (i.e. a scheme whereby practices can exclude
patients who do not meet the QOF criteria due to a
range of reasons, such as doctors being unable to
prescribe due to contraindications/side-eﬀects),1 and
if the two practices were in a UK setting it is likely that
some of the patients in our study populations would
be excluded via exception reporting due to diﬃculties
in achieving goal BP. Moreover, we have not con-
sidered the impact of known issues with respect to BP
measurement in primary care, for instance, the known
end-digit preferences when recording BP.18 Also, we
have used general practice prescribing data for the
MPR-related statistic – we have previously shown that
prescription based analysis of adherence to long-term
medications is a useful predictor of dispensing-based
adherence, with patients non-adherent in prescribing
being 81% non-adherent in dispensing.19 However,
even if the prescribedmedication was dispensed, there
is no guarantee that the dispensed medication was
subsequently consumed as directed. Extension to in-
clude dispensing data, or even home monitoring,
would obviously result in superior ‘intelligence’ and
is a desirable future direction.
A single point-in-time measure of a physiological
variable with established links to morbidity and mor-
tality (such as a target BP) can be seen as an outcomes-
oriented measure. In contrast, the MPR criterion is a
process-oriented measure, focusing on the quality of
care delivery. The ﬁve speciﬁc criteria examined
Quality indicators to measure blood pressure management over a time interval 155
herein may at ﬁrst appear somewhat arbitrary; how-
ever, they represent a continuum in progression from
point-in-time direct outcomes to more process-
oriented measures that aim to represent the quality
of care over the entire evaluation period. Point-in-
time, outcomes-based measures are important; for
instance, the QOF has been associated with positive
outcomes such as improved BP monitoring and con-
trol20,21 and better andmore equitablemanagement of
coronary heart disease across ethnic groups.22 How-
ever, as discussed in this paper, it is also important to
integrate some of the interval-based measures that
take into account the context of an entire evaluation
period. The QOF has been a bold initiative by the UK;
developing quality indicators for performance measure-
ment eﬀorts (irrespective of whether they are linked
to ﬁnancial incentives) is an ongoing eﬀort, and
countries such as the USA and NZ are drawing upon
lessons learnt from the QOF in an attempt to enhance
their current primary care healthcare systems and
processes.23,24
Conclusions
Considering only point-in-time measurements, such
as a patient’s last BP measurement, may not be the
most reliable approach in measuring and predicting
suboptimal BP control. New methods that consider
time intervals as opposed to just point-in-time
measurement have the potential to improve the
identiﬁcation of suboptimally managed patients.
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